Cobimetinib R-enantiomer (GDC-0973.

Cobimetinib racemate is the racemate form of Cobimetinib (GDC-0973, XL518), which is a potent, highly selective inhibitor of MEK1/2..

CNX-1351 is a selective covalent Inhibitor of PI3Kα. CNX-1351 was tested against all four of the class I PI3K enzymes α, β, γ, and δ.

CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.

CN-SAH is a potent and selective inhibitor of histone methyl transferase DOT1L with IC50 of 26 nM, displays >10-fold selectivity over DNMT1, PRMT3, PRMT5, and G9α..

CNS 7056 is a new short-acting sedative/anaesthetic that acts on GABAA receptors in the brain.

CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU).

CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.

CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM)..

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMK is a RSK2 kinase inhibitor.

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo.

CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM).

CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively.

CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM).

CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay.

Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae).

Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent.

Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females.

Clocapramine hydrochloride hydrate is an antagonist of the D2 and 5-HT2A receptors.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases.

Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities.

Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.

Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma..

Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor.